As new immunotherapies continue to be developed, assumptions regarding patterns of clinical responses based on responses to chemotherapy are no longer tenable: appropriate clinical trial methodology must be employed since their novel mechanisms of action lead to novel patterns of clinical response.  Employment in clinical trials of imaging techniques and criteria can be of considerable help in this regard, as discussed in this White Paper.